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Abstract The objective of this study was to assess the
prevalence of and risk factors for primary headaches in
juvenile myoclonic epilepsy (JME). Headache was classi-
ﬁed in 75 patients with JME using a questionnaire, and its
prevalence was correlated with the literature on the general
population and clinical data. Headache was present in 47
patients. Thirty-one had migraine [20 migraine without aura
(MO), 11 migraine with aura (MA)]. Fourteen patients with
migraine had tension-type headache (TTH) in addition.
Sixteen had only TTH. Comparison with the general popu-
lation revealed a signiﬁcantly higher prevalence of migraine
(RR 4.4), MO (3.6), MA (7.3) and TTH (3.4) in JME. Risk
factorsformigraineandMOwerefemalegenderandforMA
family history ofmigraine inﬁrst-degree relatives. Migraine
and MA were associated with fairly controlled generalized
tonic clonic seizures, MO with absences. Together with its
strong genetic background, JME appears to be an attractive
homogenous subtype of epilepsy for genetic research on
migraine.
Keywords Juvenile myoclonic epilepsy  Headache 
Migraine  Prevalence
Introduction
Both primary headache disorders and epilepsies are chronic
neurological pathologies with episodic manifestations [1].
Beyond their high prevalence in the general population,
Ottman and Lipton [2] have demonstrated that migraine and
epilepsy are often comorbid. Risk factors (positive family
history, comorbid depression) or triggers (alcohol, menses,
and irregularity of sleep) as well as prophylactic drugs
(valproate, topiramate) are shared by both. This suggests
that migraine and epilepsy may have some common patho-
physiological mechanisms. Proposed mechanisms include
an increased excitability of the cortex accounting for the
increased risk of migraine and epilepsy [3] or seizures being
triggered by migraine attacks, as the term migralepsy of the
International Classiﬁcation of Headache Disorders (ICHD-
II) [4] suggests. It is well known that seizures can trigger
secondary headache attacks as well (postictal headache,
ICHD-II 7.6.2) [4, 5].
Juvenile myoclonic epilepsy (JME) is a generalized
epilepsy syndrome [6] with a prevalence of 4–10% of all
patients with epilepsy [7]. It manifests typically in the
second decade [8]. The main seizure types are myoclonic
jerks, generalized tonic-clonic seizures and, less frequently,
absences [9]. The syndrome has a strong genetic back-
ground with at least 40% of patients presenting a positive
family history [10]. Intensive genetic studies could identify
genes associated with JME coding for various ion channels,
but also acetylcholine receptors, lysosomal membranes,
and for the regulation of apoptosis (review in [11]). Typical
interictal EEG-ﬁndings are generalized polyspikes and
generalized spike and wave discharges [12]. Despite being
generalized, these EEG ﬁndings may have a lateralized
maximum in about one-third of patients [13], and photo-
sensitivity can be recorded in 30–90% of patients [14].
In this work, we analysed the correlation between JME
and headache. Using a retrospective approach, we studied
the prevalence of interictal headaches in a group of patients
with JME who had presented to our outpatient epilepsy
clinic. Headaches were characterized according to the
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DOI 10.1007/s10194-011-0332-6ICHD-II [4] and correlations were sought between the
characteristics of the headache and the clinical manifesta-
tions of JME.
Patients and methods
Study population
Patients with JME were retrospectively identiﬁed by
searching our electronic medical records from 1999 to
2008 for the keywords juvenile myoclonic epilepsy, JME
and orthographically related terms. All patients who had
been given the diagnosis of JME according to the criteria of
the International League Against Epilepsy (ILAE) were
included [15]. A standardized letter was sent to these
patients, which obtained written informed consent and
included instructions stating that the study was interested in
comorbidities of epilepsy. The patients were asked to give
information on personal details (age, gender, family history
of migraine, migraine in ﬁrst-degree relatives, family his-
tory of JME, and JME in ﬁrst-degree relatives) and medi-
cation to be chosen from the following list: anti-epileptic
drugs, anti-pain medication (non-opioid pain medication
and triptans), anti-depressants, and anti-hypertensive drugs
(beta blockers, ACE inhibitors, AT1 antagonists). They
were asked to report a temporal relation between their
headache attacks, if present, and their seizures: no relation,
headache before, during or after the seizure. The self-
administered German language headache questionnaire
should only be completed for the headaches unrelated to
seizures to avoid a confusion of the primary headaches
with the secondary headache postictal headache. For this,
headache starting within 3 h after the seizure was assessed
to be postictal headache [4]. This questionnaire had been
validated previously according to the ICHD-II [4] for
migraine, including migraine without and with aura (MO
and MA), chronic migraine, episodic and chronic tension-
type headache (TTH), medication overuse headache and
trigeminal autonomic cephalgias [16, 17]. According to the
ICHD-II each distinct type of headache that a patient had
was separately diagnosed and coded resulting probably in
more than one diagnosis per patient [4]. Seizure activity
was taken from the patient’s personal charts and was based
on the frequency of the preceding 6 months. We catego-
rized seizure frequency as seizure-free, as rare (less than 1
per month), or as frequent (more than 1 per month).
The frequency of migraine, MO and MA in an age- and
gender-matched control group was estimated using the data
published by Lampl et al. [18]: in a ﬁrst step, the number
n of patients of each sex and age group (16–29, 30–49 and
older than 50) was identiﬁed in our patients. Second, the
prevalence P of each sex and age group (16–29, 30–49 and
older than 50) was obtained from the literature [18].
Finally, the expected number of patients with migraine,
MO and MA in the virtual control group was calculated by
multiplying n by P. Similarly, the expected frequency of
subjects with TTH in Munich (a large city in southern
Germany) was calculated according to the recent preva-
lence data of the DMKG headache study [19] using the
mean prevalence of TTH in Dortmund (a large city in
western Germany) and Augsburg (a small city in southern
Germany). This mean prevalence was chosen for Munich
to normalize for differences according to location (southern
vs. western Germany) and city size (large vs. small). When
calculating the expected frequency of headache for the
same number of virtual members of the general population,
the absolute number of MA was too low for statistical
analysis (rounded 1, data not shown). In order to achieve
more realistic numbers for MA, we thus decided to double
the size of the virtual normal population.
Evaluation of EEG
All original EEG data were retrieved from our database and
re-evaluated by an experienced electroencephalographer
(J.R.) after blinding for seizure semiology and headache
history. Interictal and ictal epileptic discharges were
identiﬁed and classiﬁed as generalized sharp wave com-
plexes, focal spikes, generalized polyspikes and photopar-
oxysmal reactions.
Statistical analysis
Statistical analysis of clinical data was performed using
SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA).
Categorical and continuous variables were analysed using
Chi-square or Fisher’s exact test (in case of expected values
\5) and two-sample t test to identify signiﬁcant correla-
tions. If appropriate, data are presented as mean ± stan-
dard deviation (SD) or as relative risk (RR). The level of
signiﬁcance was set at 0.05 in all cases.
Results
Study population and frequency of headache
122 patients with JME were identiﬁed from our database
and were sent the questionnaire. Of these, 75 returned the
completed questionnaire, resulting in a return rate of 61%.
The mean age was 33.4 ± 12.4 years. 57% of the patients
were women. The median age of seizure onset was
15 years. The seizure semiology was as follows: myoclonic
jerks were present in all patients, generalized tonic-clonic
seizures in 66 (88%), and absences in 29 (39%). EEG was
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123done in 48 patients. Although all patients were receiving
anti-epileptic treatment, only 25 (52% of 48) had no epi-
leptiform patterns. The remaining had generalized sharp-
wave complexes, focal spikes, generalized polyspikes,
photoparoxymal reactions, or a combination. To address
the possibility of a selection bias due to the return rate of
61%, respondents and non-respondents (n = 47) were
compared for epilepsy characteristics and parameters
known to be associated with headache occurrence. No
signiﬁcant difference was found between both groups for
gender (females: 43 of the respondents vs. 23 of the non-
respondents, p = 0.43), age (mean 36 ± 12 vs. 33 ±12,
p = 0.24), anti-epileptic medication, and seizure type or
frequency (data not shown).
In our group of patients with JME 47 (63%) indicated a
recurrent interictal headache. The self-administered head-
ache questionnaire identiﬁed 31 (41%) patients as having
migraine. Of these, the questionnaire identiﬁed one patient
with an additional trigeminoautonomic cephalgia (cluster
headache) and 14 (19%) who also had headache of tension
type (TTH). One of the latter also had medication overuse.
16 (21%) patients had only TTH, resulting in a total of 30
(40%) patients with TTH. 29 (39%) had episodic TTH and
one (1%) chronic TTH. The migraine could be speciﬁed as
MO in 20 patients and MA in 11. In respect of migraine
frequency, ﬁve migraine patients had chronic migraine
(one indistinguishable from medication overuse headache)
(Table 1). The remaining 28 patients (37%) had no
headache.
Of the 47 patients with headache, 33 were able to state
which began ﬁrst, headache or JME: headache came ﬁrst in
10 patients (30% of 33), JME came ﬁrst in 13 patients
(*40%) and both started at the same age in the remaining
10 (30%). Of the 11 patients with MA, 6 remembered the
beginning of their disorders: JME came ﬁrst in 3 and both
appeared at the same age in the other 3.
In addition, 18 (24%) patients also experienced head-
ache in close temporal relation to a seizure. Of these, one
reported headache prior to a seizure and 13 after a seizure.
The remaining 4 had either headache prior and after (in 2)
or during and after (in 2) a seizure.
Table 1 further shows the expected frequencies of
headache in the virtual control population estimated from
the data published by Lampl et al. [18] for migraine and by
Pfaffenrath et al. [19] for TTH. Both migraine (p\0.001)
and TTH (p = 0.001) were signiﬁcantly more frequent in
the patients with JME with a relative risk (RR) for migraine
of 4.4, for MO of 3.6, for MA of 7.3, and for TTH of 3.4.
Intrapersonal and seizure-associated risk factors
for headache
Statistical analysis of intrapersonal parameters identiﬁed
female gender as a risk factor for migraine (p = 0.01,
RR 1.6) and MO (p = 0.03, RR 1.7), and a family history
of migraine in ﬁrst-degree relatives as a risk factor for MA
(p = 0.02, RR 5.3), as shown in Table 2 (only relevant
data are shown for the purpose of clarity).
Patients with migraine, MO and TTH signiﬁcantly more
often reported taking non-opioid pain medication and
patients with MA more often used triptans.
Patients with good seizure control (i.e. seizure-free or
\1 seizure/month) did not show a correlation with the
occurrence of any kind of headache. Migraine and MA
were present signiﬁcantly more often in patients reporting
[1 generalized tonic-clonic seizure/month (p = 0.02, RR
8.5 and p = 0.02, RR 12.0) and MO in patients with [1
absence/month (p = 0.03, RR 5.5). TTH was more
Table 1 Prevalence of
headaches in JME
The prevalence of headache in
an age- and gender-matched
general population was
estimated from the literature
[17, 18]. Statistics: Chi-square,
Fisher’s exact test (in case of
expected values\5),
* p\0.05
RR relative risk
JME General population p RR
No. (%) No. (%)
Total number 75 150
Gender (female = 1) 43 (57%) 86 (57%) 1
Age (mean ± SD) 33.4 ± 12.4 (n.a.) 32.6 ± 12.5 (n.a.) 0.66
Migraine 31 (41%) 14 (9%) \0.001* 4.4
Migraine without aura 20 (27%) 11 (7%) \0.001* 3.6
Migraine with aura 11 (15%) 3 (2%) \0.001* 7.3
TTH 30 (40%) 29 (19%) 0.001* 3.4
Both, migraine and TTH 14 (19%) n.a.
Episodic TTH 29 (39%) n.a.
Chronic TTH 1 (1%) n.a.
Chronic migraine 5 (7%) n.a.
MOH 2 (3%) n.a.
TAC 1 (1%) n.a.
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123frequently found in patients with [1 absence/month
(p = 0.05).
The EEG ﬁndings generalized sharp wave complexes,
focal spikes and generalized polyspikes were equally dis-
tributed in all headache groups when compared to patients
with JME but no headache (data not shown for the purpose
of clarity). Photoparoxysmal reactions did not prevail in
patients with migraine (1 patient with photoparoxysmal
reactions out of 21 patients with migraine who had EEG),
MO (1 of 17 with MO), MA (0 of 4 with MA) and TTH
(1 of 20 with TTH) when compared with the respective
non-headache group: photoparoxysmal reactions were
present in 3 of 27 patients without migraine who had EEG
(p = 0.62 for migraine, p = 1.00 for MO and MA) and in
3 of 28 patients without TTH (p = 0.63).
Discussion
In our study, the prevalence of migraine (41%, RR 4.4) and
especially MA (15%, RR 7.3) is higher in patients with the
homogenous epilepsy subgroup of JME than expected from
studies on the general population [18, 19]. For TTH, the
prevalence of 40% (RR 3.4) in JME is also signiﬁcantly
higher than expected from our control population [19], but
it is similar to the numbers reported elsewhere (34% in
[20], 38% in [21]). The data in the literature on headache in
epilepsy are in line with our ﬁndings. However, the prev-
alence of migraine and especially MA was even higher in
our patients with JME. In respect of unselected epilepsy, a
prevalence of migraine between 8 and 24% [22–25] was
found. Syvertsen et al. [26] reported headache in 52% of
patients with unselected epilepsy. This prevalence was
similar to our study. Migraine, however, was less frequent
(only 20%). Clarke et al. [27] found a migraine prevalence
of 15% in children with the homogenous epilepsy subtype
rolandic epilepsy in contrast to 7% in non-epilepsy pro-
bands. Since JME has a strong genetic background (posi-
tive family history of seizures in at least 40% [10]),
headache and especially MA in JME, but maybe not in the
general population, might also have such a strong genetic
background. We suggest that our ﬁndings support using the
relationship of JME and MA to further study the genetics
of both disease entities. Although there are a lot more
people with MA than JME, we believe that the co-occur-
rence of epilepsy and migraine in patients with JME might
be based on shared pathophysiological mechanisms. Cor-
tical spreading depression (CSD) is thought to be a key
mechanism in the pathophysiology of both MA (e.g. [28])
and MO [29]. Therefore, the high prevalence of MA in
JME might be related to CSD starting more often in
patients with JME than without JME. This is consistent
with the hypothesis that epileptic foci and CSD might
facilitate each other [30]. It is thus possible that epileptic
discharges with or without additional cortical epileptic
signs or symptoms might stimulate the onset of CSD,
resulting in an activation of the trigeminovascular system
and, ﬁnally, in headache [31]. Parisi et al. [32] demon-
strated the relevance of such a mechanism in a case report
on a patient with photosensitive occipital lobe epilepsy and
migraine attacks triggered by intermittent photic stimula-
tion. A headache attack with migraine phenotype in
patients with epilepsy thus might be associated with
otherwise clinically silent seizures, calling into question
the rigid differentiation between interictal and ictal head-
ache. In contrast, photosensitivity was not associated with
the occurrence of headache in our patients with JME.
The association of headache with otherwise clinically
silent seizures might further be an explanation for our
ﬁnding that migraine, in general, and MA, in particular,
were more often present in patients with more than one
seizure/month. Special caution is required in the interpre-
tation of this data due to the low number of patients in the
individual groups. However, a population-based study with
1,656 participants demonstrated similar results with 5/11
(45%) subjects with active epilepsy and only 4/28 (14%)
with epilepsy in remission having migraine [33]. Since we
did not perform EEG during headache in our patients, this
possible association of headache attacks with seizures was
not tested, but might be interesting for future studies. One
consequence would be that an EEG during headache
should be aimed for, especially in patients with epilepsy,
but also in migraine patients without known epilepsy.
A complementary explanation for the correlation of
migraine with seizure frequency would be a different
genetic background in patients with migraine and JME than
in patients with JME alone, meaning that it is more difﬁcult
to treat epilepsy in patients with additional migraine.
Our ﬁnding that female gender and positive family his-
tory of migraine are risk factors for migraine, MO and MA
were expected from migraine epidemiology. The higher
intake of non-opioid pain medication in the migraine and
MO groups and of triptans in patients with MA can be
interpreted as the self-treatment of the headache attack. The
alternative interpretation that headache is produced by the
pain medication is unlikely, as only one patient was diag-
nosed with medication-overuse headache.
Since our cross-sectional study demonstrates only cor-
relations, it does not allow a conclusion on the causative
relationship between headache and JME to be drawn.
In other words, it neither argues for headache being caused
by JME nor for JME being caused by headache. Interest-
ingly, a recent case–control study from Iceland addressed
the question of a chronological interrelation of migraine
and epilepsy and was able to identify a 8.1-fold increased
risk for patients with MA of developing epilepsy later in
J Headache Pain (2011) 12:227–233 231
123life [34]. In our study, the sequence headache–epilepsy
could only be established in 6 of 11 patients with MA and
the interpretation is problematic due to the retrospective
study design. None of these 6 patients had MA prior to the
occurrence of epileptic seizures, i.e. the sequence head-
ache–epilepsy was different from that expected according
to the data from Ludvigsson et al. [34]. Although the
number of patients was very low, this might point to a
unique characteristic of MA in JME in contrast to unse-
lected epilepsy.
Limitations
One limitation of our study is that we compared our patients
to a virtual population of limited sample size instead of a
study-speciﬁc control group. However, we believe that our
approach was accurate since (a) our ﬁndings are supported
by the data in the literature as discussed above, (b) both
reference studies were from an ethnic population (Austrian
andSouthernGermany)thatwasalmostthesameasoursand
(c) the study by Lampl et al. [18] provided prevalence data
split for age and gender allowing the estimation of an age-
andgender-matchedcontrolgroup.Anotherlimitationofthe
data is the return rate of 61% for the questionnaire. If
patientswithJMEandheadachereturnedtheirquestionnaire
more frequently than patients with JME without headache, a
false high prevalence of headache would result. This sce-
nario, however, is unlikely since non-respondents differed
neither in demographic nor in clinical epilepsy characteris-
tics from respondents. Furthermore, even if all patients who
failedtorespondwereheadache-free,theprevalenceswould
be: 25% (31/122) for migraine, 16% (20/122) for MO, 9%
(11/122) for MA, and 25% (30/122) for TTH. Although this
could not be tested for signiﬁcance, these frequencies are
still higher than in our control population, but are similar to
the prevalence in patients with unselected epilepsy [24].
Nonetheless, a false high prevalence cannot deﬁnitely be
excluded, necessitating a prospective study using face-
to-face interviews for the characterization of the headache
disorder to conﬁrm our data.
In summary, we have demonstrated a higher prevalence
of MA (and to a lesser degree also of migraine, in general,
and TTH) in patients with JME than in the general popu-
lation and in patients with unselected epilepsy. This sug-
gests a common, so far unknown, pathophysiological
mechanism of JME and migraine. JME is a homogeneous
epilepsy syndrome and seems to be a good candidate for
headache research in epilepsy.
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